- Home
- INVE vs WHWK Comparison
INVE vs WHWK Comparison
Compare INVE & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVE | WHWK |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | N/A | 22 |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.8M | 179.8M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | INVE | WHWK |
|---|---|---|
| Price | $3.74 | $4.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $5.50 | ★ $7.00 |
| AVG Volume (30 Days) | 120.7K | ★ 188.1K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $60,219,000.00 | N/A |
| Revenue This Year | $22.10 | N/A |
| Revenue Next Year | $20.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.21 | N/A |
| 52 Week Low | $3.00 | $1.39 |
| 52 Week High | $4.08 | $4.40 |
Technical Indicators
Market Signals| Indicator | INVE | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 58.82 | 66.97 |
| Support Level | $3.18 | $1.84 |
| Resistance Level | $3.85 | $4.40 |
| Average True Range (ATR) | 0.18 | 0.29 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 69.12 | 88.75 |
Price Performance
Historical ComparisonAbout INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.